Research brief • June 8, 2026
NAD+ and LL-37: Source Check for Research Readers
The midnight PDR video queue focused on NAD+ and LL-37. This article turns those short-form research angles into a source-first reading guide: what each topic is, what kind of evidence shows up in searches, and where trend claims need boundaries.
Save the source-checking prompts.
Get education-first checklists for reading study abstracts, supplier pages, COAs, and social-media peptide claims.
Quick answer: these are not the same research category
NAD+ is usually discussed as a central redox cofactor involved in cellular energy metabolism, mitochondrial biology, DNA-repair signaling, and aging-biology research. It is not a peptide, but it often appears beside peptide-adjacent topics because both categories show up in longevity and metabolism conversations.
LL-37 is different. It is a human cathelicidin-derived antimicrobial peptide studied in host-defense, epithelial-barrier, inflammation, infection-model, and immune-signaling contexts. That does not mean every online immune or wellness claim is supported; it means the first reading step is to identify whether the source is a review, a cell model, an animal model, a human observational study, or a clinical-trial record.
1. NAD+ searches: metabolism language needs careful endpoints
NAD+ source checks should separate broad mechanism language from measured outcomes. Papers may discuss mitochondrial function, sirtuin biology, redox state, PARP activity, cellular stress response, or age-associated changes in NAD+ metabolism. Those are useful concepts, but they are not the same as proof of a personal outcome.
When a post says NAD+ “supports energy,” “helps aging,” or “boosts mitochondria,” ask what the cited source actually measured. Was it a biochemical marker, a cell-culture pathway, an animal endpoint, a small human biomarker study, or a registered clinical trial? The evidence level changes how confident the language should be.
2. LL-37 searches: host-defense does not equal a treatment claim
LL-37 is commonly described in the literature as part of innate immune defense. Researchers study it around antimicrobial activity, barrier tissues, inflammatory signaling, wound and epithelial biology, and host-pathogen interactions. That terminology can sound powerful in social content, so the claim boundary matters.
“Studied in host defense” is a safer phrase than “treats infection” or “fixes immunity.” Research readers should look for study context, sample type, disease model, endpoints, and whether a source is describing natural LL-37 biology versus an experimental intervention. Avoid turning immunology terms into protocols or medical advice.
3. What PubMed and ClinicalTrials.gov can clarify
PubMed helps define the category
Use PubMed to see whether the topic is mainly mechanism-heavy, review-heavy, animal-model-heavy, or backed by human clinical studies.
ClinicalTrials.gov helps locate human trial context
Trial records can show condition, design, recruitment status, enrollment targets, and endpoints, but a listing is not proof that results are positive or broadly applicable.
Regulatory silence is not approval
If an online page implies consumer use based only on research terminology, slow down. Research interest is not the same thing as an FDA-approved indication or personal-use guidance.
Trend language needs boundaries
Words such as “proves,” “cures,” “guarantees,” “safe,” “best,” or “protocol” should trigger a source check before the claim is repeated.
Claim-check prompts for today’s videos
- For NAD+: Is the claim about a biochemical pathway, an animal model, a supplement/drug trial, or a measured human endpoint?
- For LL-37: Is the claim about naturally occurring cathelicidin biology, an experimental peptide model, or a clinical intervention?
- For both: Does the content cite a primary source, or only repeat social-media shorthand?
- For both: Does the source avoid dosing, stacking, sourcing, and treatment-plan language?
Sources to start with
Get the free Peptide Research Starter Kit.
Claim-checking prompts, COA due-diligence notes, and article drops. No dosing, protocols, or medical advice.